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Abstract
Dengue is an increasingly common mosquito-borne, flaviviral disease of significant pub-
lic health concern. The disease is endemic throughout tropical and subtropical regions, 
placing almost half of the world’s population at risk, and each year approaching 100 
million people in around 130 countries are infected. There is acknowledged to be four 
antigenically distinct serotypes of the virus, and arguably a fifth, each of which elicits 
a full spectrum of clinical disease. This ranges from asymptomatic self-limiting infec-
tion to life-threatening severe manifestations characterized by plasma leakage, bleeding, 
and/or organ failure. Recovery from primary infection by one serotype provides life-
long immunity against reinfection by that particular serotype, whereas with subsequent 
infections by other serotypes, the risk of developing severe dengue is increased. Rising 
mortality and morbidity rates caused by infection in recent years are attributable partly 
to a lack of availability of effective antiviral therapies and vaccines. In this context, early 
detection of infection with sensitive and specific laboratory tools and the prompt clinical 
management of this disease is a health care priority. Although a variety of techniques are 
currently used for laboratory diagnosis of dengue, no single methodology satisfies the 
ideal requirement for both sensitivity and specificity, while also being rapid and inex-
pensive. Newer detection tools that can fill this acknowledged gap in dengue diagnosis 
are urgently required.
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1. Introduction
Dengue is a mosquito-borne viral disease that has a wide-ranging geographical distribution 
throughout the tropics and subtropics. It is estimated that currently over 3.9 billion people are 
at risk of infection [1], with 96 million notified clinical cases per year in at least 128  countries 
worldwide [2]. Dengue virus (DENV) is transmitted by mosquitoes of the Aedes genus, 
 primarily Ae. aegypti, but also Ae. albopictus and Ae. polynesiensis [3]. DENV is a  member of 
the family Flaviviridae [4], which also includes the other major human pathogens West Nile, 
yellow fever, Zika, Japanese encephalitis, and tick-borne encephalitis viruses. Four sero-
types of the virus (DENV-1 to DENV-4) have been known for many years, while a putative 
fifth  serotype, DENV-5, was identified recently [5]. This new subtype was identified during 
screening tests on virus samples collected during an outbreak in Malaysia in 2007 [6].
DENV infection may result in a progressive scope of clinical sequelae, viewed traditionally 
as ranging from asymptomatic infection through to dengue fever (DF) and the more severe 
disease manifestations of dengue haemorrhagic fever (DHF) and dengue shock syndrome 
(DSS). More recently [7], the World Health Organization proposed a revised classification that 
categorizes infection as follows: (1) dengue; (2) dengue with warning signs (abdominal pain, 
persistent vomiting, fluid accumulation, mucosal bleeding, lethargy, liver enlargement, and 
increasing hematocrit with decreasing platelets); and (3) severe dengue (dengue with severe 
plasma leakage, severe bleeding, and/or organ failure). Asymptomatic infections are charac-
terized by undifferentiated fever with or without rashes. In the majority of clinical cases, the 
initial presentation of dengue is not apparent until clear signs and symptoms develop. In turn, 
this delay limits the ability to make an early and accurate clinical diagnosis. Moreover, there 
are no specific therapies for dengue, such as anti-viral drugs. Any treatment is essentially sup-
portive, and thus, there is a very important challenge in making an informed estimate of the 
severity of a patient’s disease as early as is practicable. The preliminary stages of DF are often 
confused with other febrile tropical diseases [8], which may lead to inappropriate therapy.
Although very recently, the first licensed dengue vaccine (DENV-1 to DENV-4 chimera 
 constructed on a yellow fever 17D backbone, recombinant, live attenuated, tetravalent virus 
(CYD-TDV; Dengvaxia®, Sanofi Pasteur)) has been registered for use [9], major challenges 
to vaccine effectiveness and long-term safety in the administered population remain. This 
scenario, therefore, still demands a quick and reliable diagnostic approach. While a variety of 
laboratory diagnostic techniques have been in use for many years, each has its limitations [10], 
to date no tool proving to be reliable, rapid, and cost-effective. There is, therefore, a pressing 
need to improve the way in which dengue is diagnosed. The overall scenario calls for the 
development of reliable and rapid dengue diagnostic tools.
2. Current laboratory methods for dengue diagnosis
2.1. Virus isolation
Virus isolation is considered to be the gold standard technique in dengue diagnosis [11]. 
Isolation is highly successful when specimens are collected in the viraemic period, which 
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starts 2–3 days before the onset of fever and lasts for a further 2–3 days [12]. Routinely, serum 
is the primary choice of sample. In addition, other types of specimen, including plasma, 
peripheral blood, cerebrospinal fluid, pleural fluid, and tissues of reticuloendothelial origin 
such as liver, spleen, lymph nodes, lung, and thymus, are of substantial importance [7, 12, 
13]. Diagnostic sensitivity is dependent upon the timing of specimen collection, proper stor-
age, and transportation. Since the DENV virus particle is heat-labile, appropriate handling 
and prompt delivery to the laboratory is required. When storage is warranted, a standard 
refrigerator temperature (~4°C) is quite appropriate in the short term, while for a longer dura-
tion, freezer temperatures of −20 or −70°C are recommended. In the latter case, they should be 
maintained in order to prevent thawing [13].
There are different methods available for the isolation of DENV including inoculation of spec-
imens into mosquitoes (adults or larvae); various in vitro insect or mammalian cell cultures; 
and injection intra-cerebrally in mice [12, 14–16].
2.1.1. Specimen inoculation into mosquitoes
Inoculation of specimens into both adult and larval mosquitoes with the objective to isolate 
DENV is considered to be the most sensitive and specific culture technique. Generally, mos-
quitoes belonging to the Toxorhynchites genus are used for this purpose. The advantage of 
these over Aedes mosquitoes is that the former has an unusual life cycle in not being hema-
tophagous, so may be handled with impunity. In addition, the comparatively larger size of 
Toxorhynchites facilitates easier introduction of inocula. However, the fact that between 5 and 
20 mosquitoes are needed to produce results of higher sensitivity is considered a drawback of 
this method. Alternatively, adult male Ae. aegypti and Ae. albopictus mosquitoes are also useful 
for virus isolation [17, 18]. The preferred route for specimen inoculation of mosquitoes is intra-
thoracic. Incubation for 14 days at 32°C following inoculation precedes mosquito storage at 
−70°C [19]. Successful virus infection of mosquitoes is confirmed by the detection of antigen in 
a smear prepared by crushing of mosquito heads on a microscope slide followed by serotype-
specific immunofluorescence. A preparation of thorax-abdomens can also be tested for virus 
by plaque assay or plaque reduction neutralization test (PRNT) using monospecific dengue 
virus antisera targeted against different DENV serotypes [20]. The labor-intensive process of 
raising mosquitoes requires arranging for a second mosquito species to serve as a food source 
(because Toxorhynchites mosquitoes are carnivorous). In addition, the requirement for facili-
ties with capacity to rear and handle infectious Aedes mosquitoes while adhering to stringent 
health and safety protocols is beyond the capability of most laboratories and remains a major 
obstacle. Similarly, the need for both specialist containment and highly skilled technicians 
in order to perform direct mosquito inoculation has combined to make in vitro cell culture a 
preferred option [21].
2.1.2. Mosquito or mammalian cell line culture
In vitro culture of cell lines is a technique being developed as an alternative tool for virus 
isolation and aimed at overcoming the pitfalls involved in mosquito inoculation. However, 
thus far the variety of approaches to cell line culture is limited by the lower sensitivity of 
results obtained. Cell line cultures from Ae. albopictus (C6/36), Ae. pseudoscutelaris (AP-61, 
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AP-64), and Tinissa amboinensis (TRA-284) are different choices for routine DENV isolation 
[22–24]. All three of these have distinct benefits and drawbacks, so preference of use should 
be made on a case-by-case basis. In a comparative study, the virus isolation rate was found 
to be highest in TRA-284, followed by AP-61 and C6/36 [24]. In contrast, C6/36 cells were 
preferable for detecting infected cells by the direct fluorescent antibody test (DFAT). The 
utility of the C6/36 cell line method to isolate virus from tissue samples derived from fatal 
cases of dengue has been demonstrated [16]. Problems with AP-61 and TRA-284 include 
frequent cell clumping and difficulties in formation of a monolayer in a tissue culture flask. 
Some dengue viruses, especially wild types, do not produce cytopathic effects on these cell 
lines [24], which limits usage of the plaque assay and PRNT for virus quantification and 
virus-neutralizing antibody detection. Therefore, for specific diagnosis, immunoassays 
should be used.
Alternatives for isolating virus are mammalian cells such as Vero and BS-C-1 (both derived 
from African green monkey kidney), LLCMK2 rhesus monkey kidney, PS (porcine kidney), 
and BHK 21 (baby hamster kidney). While these cell cultures are used widely in the PRNT, 
they produce less sensitive results. PRNT is considered as the benchmark means to character-
ize and quantify circulating levels of anti-DENV neutralizing antibody [25–27].
2.1.3. Intra-cerebral injection in mice
The oldest and least sensitive method for virus isolation is intracerebral inoculation of suck-
ling mice. This does, nonetheless, offer a considerable benefit in enabling evaluation of the 
neutrotropic characteristics of the dengue virus particle in vivo. In most cases, mice develop 
encephalitis symptoms [28]. However, virus identification is generally accomplished by 
immunofluorescence methods with serotype-specific anti-dengue antibodies applied to 
infected cells or brain tissue of mice. This is a cumbersome procedure, and the need for a high 
specification laboratory microscope combined with difficulties in maintaining viability of the 
virus in specimens limit its use on a routine basis.
2.2. Viral nucleic acid detection
DENV is a single-stranded positive-sense RNA virus of approximately 50 nm in length. The 
11 kb genome of each virion encodes three structural proteins (capsid, C; precursor mem-
brane, prM; and envelope, E) and seven non-structural (NS) proteins (NS1, NS2A, NS2B, 
NS3, NS4A, NS4B, and NS5). These non-structural proteins play roles in viral replication and 
assembly. Structurally, a virion consists of a nucleocapsid, enveloped by an outer glycopro-
tein shell and an inner lipid bilayer. Surface projections in the lipid membrane consist of E and 
membrane (M) glycoproteins [4].
Nucleic acid amplification tests and identification of virus antigen or antibody serve as the 
predominant means of detection of DENV, based on the molecular or immunological response 
to specified viral structural components. Commonly used methods are reverse transcription 
polymerase chain reaction (RT-PCR), nucleic acid sequence-based amplification (NASBA), 
and transcription-mediated amplification (TMA).
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2.2.1. Polymerase chain reaction
Virus RNA genome detection tests are faster and considered more sensitive than virus iso-
lation and its detection. Thoughtful design of primer sequence may be applied to not only 
distinguish the binary presence of the target virus but also determine detailed features of 
the viral genome such as serotype or polymorphisms. Type-specific primers and consensus 
sequences that are located in different genes of most flaviviruses including dengue, such as 
those for E, NS1, NS3, and NS5, have been used extensively for the detection and identifica-
tion of DENV [29–32]. For a PCR run, DENV RNA should pass through a conversion step to 
complementary DNA (cDNA) by a process of reverse transcription (RT). Conventional PCR 
can be used to identify the presence or absence of a target sequence in a given sample when 
reaction products are visualized by agarose gel electrophoresis [33], Southern blot [34], or 
colorimetric enzyme-linked immunosorbent assay [35]. While easy to enact, these conven-
tional procedures have a limited inference in comparison to more versatile PCR systems. They 
are considered less robust as multiple handling steps are required, which increase the risk of 
contamination and hence the production of false-positive results.
Modification of protocols to make use of nested primers aims to reduce non-specific detection 
by negating improper primer binding. In nested PCR, targets are detected by using two sets 
of primers involving a double process of amplification. However, the greater manipulation of 
the sample that this technique involves may raise the risk of contamination of the amplicon 
product. Multiplex PCR is an adaptation that allows simultaneous amplification and detec-
tion of multiple target amplicons, which can be used to great effect in distinguishing condi-
tions such as viral serotype. Both methods have been found to increase the sensitivity and 
specificity of the test and are preferred for the diagnosis of DENV [33, 36].
Real-time PCR, also known as quantitative PCR (qPCR), is a far more robust assay format 
than conventional PCR, over which it has many advantages including rapidity, quantita-
tive measurements, lower contamination rate, higher sensitivity, and specificity, and ease of 
standardization. Furthermore, qPCR renders post-PCR procedures such as electrophoresis 
or blotting unnecessary, minimizing the chance of contamination. As per conventional PCR, 
qPCR primer sequence can be specified to detect specific DENV to a threshold that is usually 
less than 100 plaque-forming units [33, 37].
With advances in diagnosis, the two-step nested RT-PCR protocol, modified to a single-step 
multiplex RT-PCR for detection and typing of DENV, is well established [33]. In nested PCR, 
targets are detected by using two sets of primers involving a double process of amplification. 
A nested PCR assay was developed using DENV consensus primers located in the C and 
prM genes that amplify a 511-bp product in a reverse transcriptase PCR followed by a nested 
PCR with primers specific to each DENV serotype [33]. Application of multiplex qPCR for 
the diagnosis of dengue has been described by various studies [36–38]. Each has concluded 
that this technique demonstrates superior analytical and clinical performance, as well as sim-
pler workflow, than the heminested RT-PCR [38]. More recently, several investigators have 
reported on fully automatic real-time RT-PCR assays for the detection of DENV in acute-
phase serum samples [39–43].
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2.2.2. Nucleic acid sequence-based amplification
Nucleic acid sequence-based amplification (NASBA) is a one-step transcription-mediated 
isothermal process for amplifying RNA. Throughout the amplification reaction, a constant 
temperature of 41°C is maintained. The reaction mixture contains three enzymes: avian 
myeloblastosis reverse transcriptase (AMV-RT); T7 RNA polymerase; and RNase H with two 
short, single-stranded DNA primers. Multiple transcription of RNA copies of DNA products 
that are produced from the initial reverse transcription step are attributable for the exponen-
tial kinetics of NASBA. Hence, synthesized RNA pools are detected by fluorescence. These 
“molecular beacons” are single-stranded hairpin-shaped oligonucleotide probes showing 
fluorescence at the 5′ end and with a fluorescence quencher at the 3′ end. When presented 
in an amplification reaction with their amplified target RNA, a stable hybrid is formed [44].
Studies have found a sensitivity of 98.5% and specificity of 100% when they detected DENV 
with NASBA [45, 46]. The effectiveness of this method has also been described for detect-
ing dengue virus within mosquitoes [47]. It is considered more efficient than PCR in that it 
bypasses the use of a thermal cycler, which makes it both cost-effective and rapid (<1 day).
2.2.3. Reverse transcription loop-mediated isothermal amplification
Loop-mediated isothermal amplification (LAMP) is a novel PCR method that is based on the 
principle of a strand displacement reaction involving a stem loop structure that amplifies the 
target genome [48]. Its advantage over other amplification methods is the ease of monitoring 
of amplification; pyrophosphate ions produced as a by-product of reaction substrate deoxy-
nucleotide triphosphates form a white precipitate of magnesium pyrophosphate that can be 
visualized by the naked eye, measured by turbidometer, detected by hand-held UV torch, 
or even following staining with SYBR green® or ethidium bromide [49, 50]. Furthermore, 
it takes less than one hour to yield results compared to the 3–4 h typically needed to run 
RT-PCR [51].
Several studies have found RT-LAMP to be a superior tool to RT-PCR in terms of sensitiv-
ity and specificity for detection and accurate differentiation of flaviviruses [49, 50, 52, 53]. 
Sensitivity of the tool is variously reported at 100% [49, 52, 54], with a lowest detection limit 
of 100 copy numbers of RNAs, while specificity ranges from 87.5 to 100% [49, 50, 52, 53].
2.3. Serological methods
2.3.1. Antigen detection
During the febrile phase of dengue illness, DENV antigens may be detected in peripheral 
blood leukocytes, liver [54], and lung at autopsy, and less often in the thymus, lymph nodes, 
skin, spleen [55], bone marrow, and serosa [56]. Immunohistochemistry and enzyme immu-
noassay (EIA) are useful techniques to detect dengue antigens in tissue sections (frozen, par-
affin-embedded) using labeled monoclonal antibodies that are visualized with markers such 
as fluorescent dyes (fluorescent antibody), enzymes (immunoperoxidase and avidin-biotin 
enzyme) or colloidal gold. Given the inconvenience of collecting samples on which to apply 
these techniques, their utility has been limited for routine laboratory tests. Instead, assays 
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have been developed against intact virus particle and recombinant viral proteins, with NS1 
and E protein detection available commercially [57, 58].
2.3.2. Non-structural proteins (NS1 and NS5)-based assay
Non-structural gene, NS1, is a highly conserved glycoprotein produced by all flaviviruses 
in both membrane-associated and secreted forms, and which is essential for viral replication 
and viability [59]. Localized to cellular organelles, this antigen is secreted abundantly in sera 
of patients during virus replication and the early stage of infection [58]. A unique feature of 
this protein is its secretion by mammalian cells as hexamers (dimer subunits only), while it is 
not secreted by insect cells, including those of mosquitoes. Glycosylation is believed to be an 
important step for protein secretion. It can be identified in peripheral blood prior to formation 
of antibodies, and the detection rate is higher in acute primary infection from the day of onset 
of fever to day 9 [60, 61]. NS1 is also a complement-fixing antigen that elicits a very strong 
humoral response.
Several recent studies have addressed the use of NS1 antigen and anti-NS1 antibodies as a 
tool for dengue diagnosis [62–65], with higher specificity for determination of homologous 
serotypes by serotype- and group-specific NS1 capture ELISA [62, 66], and a detection sen-
sitivity of 1–4 ng/ml NS1 in blood [67]. This tool can be utilized to differentiate between pri-
mary and secondary dengue virus infections, as proven by the highly correlated results of 
NS1 serotype-specific IgG (determined by ELISA) and PRNT [43, 68]. The NS1 serotype-spe-
cific IgG ELISA worked reliably for serotyping dengue virus in convalescent phase sera from 
patients with primary infection and also in acute phase sera from patients with secondary 
infection (in which the serotype that caused the first infection would be detected), but not so 
with convalescent phase sera from patients with secondary infections. Different commercial 
assays to detect NS1 antigen are available, including Panbio dengue virus Pan-E NS1 early 
ELISA (Alere); dengue virus NS1 antigen ELISA (Standard Diagnostics); Platelia NS1 antigen 
ELISA (Bio-Rad). However, none of these have excellent sensitivity, ranging from 45 to 57% 
[69]. NS1 ELISA has a noted lower sensitivity in sera from patients infected with DENV-4. 
This may be due to possible quantitative differences in the secretion of NS1 antigen by distinct 
serotypes [70].
Dengue non-structural protein NS5, which plays a vital role in dengue replication, is the larg-
est and most well conserved of the flavivirus proteins [71]. One study demonstrated reliable 
results in diagnosing and differentiating DENV from West Nile virus and St. Louis encephali-
tis (SLE) virus using an immunoassay designed to targeting NS5 antigen [72]. However, ques-
tions arise as to its specificity since NS5 amino acid sequence homology between West Nile, 
dengue, and SLE viruses is more than 75% [72], hence a greater chance that results would be 
affected by cross-reactivity.
2.4. Antibody detection
DENV-specific IgM antibodies start to appear after 4–5 days of primary infection and are 
measurable for up to 3 months [73]. IgG antibodies appear about a week after onset of fever, 
persist at high titres for several weeks and then decline; however, IgG may be detected for 
decades [74]. IgG1 and IgG3 are the subclasses that are mainly induced [75, 76]. Following 
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secondary infection, memory B cells are stimulated in response to secrete DENV-specific IgG 
that is measurable even on the first day of symptoms and the titre remains much higher com-
pared to during primary infection. In secondary dengue, the IgM response is variable and, in 
some cases, even undetectable. The most commonly used antibody detection techniques for 
dengue diagnosis are haemagglutination inhibition (HI) and ELISA for IgM or IgG [77].
2.4.1. Hemagglutination inhibition
The hemagglutination inhibition (HI) method was a routinely utilized method before the 
development of the fast and easier antibody detection methods immunofluorescence assay 
(IFA) and ELISA. Due to its high degree of sensitivity and ease of application, HI is still used 
sometimes in developing countries. The test is based on the principle whereby the property of 
erythrocyte agglutination by dengue proteins is inhibited when dengue antibodies are pres-
ent in serum at a sufficient concentration [78]. The most important practical limitations of the 
HI test are its poor specificity, requirement for paired samples, and the inability to distinguish 
dengue serotype [35]. Moreover, the test fails to differentiate dengue from the closely related 
Japanese encephalitis and yellow fever flaviviruses [11, 78, 79].
2.4.2. E/M-specific capture IgM and IgG ELISA
Methods of detection of dengue by capturing E/M-specific IgM and IgG antibodies are rel-
atively efficient in terms of their higher diagnostic sensitivity, specificity, simplicity, and 
feasibility of use in low-resource countries where facilities for molecular diagnosis are not 
standardly available [80–82].
In IgM antibody capture (MAC)-ELISA, the total IgM in a patient’s sera is bound by anti-μ 
chain-specific antibodies precoated on the microtitre plate [83]. Due to its rapid production 
then gradual waning after 2–3 months ELISA based on IgM detection is considered sensitive 
in early dengue infection, while not being suitable in cases of prolonged infection [11, 84].
E/M-specific IgG antibody capture ELISA, also called GAC-ELISA, enables measurement 
of IgG for up to 10 months after infection, thereby facilitating detection of recent and past 
dengue infection. In general, IgG ELISA lacks specificity within the flavivirus sero-complex 
groups; however, the IgG response to prM is specific to individual flaviviruses [85]. Dengue 
secondary infection progresses to severe dengue, so it is important to differentiate secondary 
from primary infection. IgG avidity ELISAs can be used to determine whether an infection is 
primary or secondary [86, 87]. The principle behind this method is that antibodies first syn-
thesized after primary infection exhibit a lower affinity for antigen than do those produced 
later during secondary infection.
Classification of primary and secondary infections can also be defined in terms of the ratio 
of anti-DENV IgM to IgG antibodies. A higher IgM/IgG ratio specifies the infection as 
being primary, for which a ratio value of 1.2 is considered as a distinguishing cut-off. 
However, the most reliable way to demonstrate active infection would be a significant 
(fourfold or greater) rise in IgM and/or IgG antibody titres between acute and convalescent 
phase sera [88].
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Cross-reactivity between flavivirus antigens is the major issue that lowers the specificity of 
ELISA. While this may be reduced by detecting E/M- and NS1-specific anti-dengue virus IgM 
antibodies, E/M-specific IgG elicited by different flavivirus sero-complexes are highly cross-
reactive [10, 11]. In order to increase the specificity of results analysis of paired serum samples 
from both acute and convalescent phases is strongly recommended [10, 11].
2.5. Rapid diagnostic test
Immunochromatographic tests are developed to meet the need for rapid methods of dengue 
diagnosis. The value of the immunochromatographic format is its rapid attainment of a result 
by virtue of a color change that is visible to the naked eye within 10–15 min. Tools are based 
on the detection of anti-dengue IgM and IgG antibodies and of dengue antigens. A num-
ber of studies have evaluated dengue rapid diagnostic tests (RDTs) [89–93]. Commonly used 
RDTs are Duo IgM and IgG Rapid Test Strip (Panbio); Bioline Dengue IgG/IgM (Standard 
Diagnostics); VScan (Minerava); Smartcheck (GlobaleMed); Denguecheck-WB (Tulip); and 
Dengue IgG/IgM (Core). With acute phase samples, the diagnostic accuracy of the tests has 
not been established reliably, but manufacturers’ claimed performance ranges from 76 to 
100% sensitivity and exceeding 99% specificity. In contrast, markedly different results were 
claimed independently [92], suggesting most RDTs are unsuitable for dengue diagnosis as 
they have poor sensitivity and specificity. A preliminary trial of dengue from Nepal has 
reported a similar finding when rapid immunochromatographic tests are comparing with 
ELISA; the former tool did not prove sufficiently reliable with regard to either sensitivity or 
specificity [82]. In order to overcome the limitations posed by RDTs, techniques have been 
modified whereby dengue NS1 antigen is detected in combination with anti-glycoprotein E 
IgM and IgG antibodies [94].
2.6. Dengue virus serotyping and genotyping
Detection and serotyping of dengue viruses are performed by molecular methods such as 
PCR (nested, semi-nested, and multiplex RT-PCR) using serotype-specific primers [95, 96]. 
Following RT-PCR, the amplified product is subjected to nucleotide sequencing. The most 
commonly used commercial sequencing technique for amplicon purification and sequencing 
is QIAquick PCR Purification Kit (Qiagen). Both strands of the PCR product are sequenced 
in order to avoid discrepancies. Gene sequences obtained for DENV strains are submitted 
to the GenBank database (http://www.ncbi.nlm.nih.gov). A basic local alignment search tool 
(BLAST) algorithm performed against information stored in the database finds regions of 
local similarity between nucleotide sequences. This may yield functional and evolutionary 
clues about the structure and function of any novel sequence.
3. Diagnostic limitations
A lack of sensitive, specific, rapid, and cost-effective assays remains the major hurdle to 
the development of diagnostic tools for dengue virus detection. Although virus isolation is 
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more specific, it is limited by being time-consuming and expensive, needing expertise, an 
inability to differentiate primary and secondary infections, and requiring acute samples (0–5 
days post onset of fever) [13]. Nucleic acid (RNA) detection, although sufficiently sensitive 
and specific to identify both serotype and genotype in a short time is also restricted by the 
need for an acute sample, skilled handling, and by its incapacity to distinguish primary from 
secondary infections [78]. Furthermore, it is an expensive tool that is not affordable by all 
laboratories. While these limitations are being overcome by the detection of NS1 antigen, its 
sensitivity compared to genome detection methods is poor and cannot be guaranteed [68]. 
Tests that measure anti-dengue IgM antibodies are useful only for the first 4–6 days of infec-
tion. Also, IgM levels in secondary infection are quite low and could be below the threshold 
for detection. Moreover, IgG specificity is reduced due to cross-reactivity among flaviviruses 
[10, 11, 97].
4. Future directions
Challenges in developing a highly sensitive and specific diagnostic tool should be addressed. 
Possibilities for improvement lie in combining current techniques that could enhance both 
sensitivity and specificity. A rapid, sensitive test that combines detection of NS1, IgG, and 
IgM, thereby enabling diagnosis of infection throughout the course of illness, would provide 
a significant advancement in dengue diagnostics.
A potential tool to detect dengue is based on detection of the light transmission spectrum 
recorded in the near-infrared range (NIR). NIR spectroscopy is a fast, multicomponent 
assay that enables non-invasive, non-destructive analysis, in this case of human blood 
samples. NIR spectroscopy has become a widely used analytical method in the agricul-
tural, chemical, petrochemical, pharmaceutical, and medical industries [98]. It may also 
find an application in the medical diagnostics field and preliminary investigations are 
underway. In general, optical spectroscopy is a technique that utilizes the light energy-
dependent interaction with a sample (electromagnetic radiation usually quantified by 
wavelength). Biological substances can interact with light energy and produce a variety of 
optical responses—transmission, reflection scattering, and absorption. By scanning C6/36 
cells either infected or not infected with DENV and/or mouse monoclonal hybridoma anti-
bodies against DENV, differences in NIR spectra may indicate dengue infection. Analysis 
and standardization of these optical responses could literally help to shed light on dengue 
diagnosis in the future.
Considerable research has been performed to develop biosensors as effective tools for infec-
tious disease diagnostics [99, 100]. A biosensor based on silicon nanowire can detect the 
‘reverse transcription polymerase chain reaction’ product of dengue in less than 30 min. 
Peptide nucleic acid probes fixed in silicon nanowires recognize complementary DNA frag-
ments [100]. Sensitive and specific results from these techniques could offset the other labor-
intensive and time-consuming laboratory tests requiring trained laboratory staff.
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